- Home
- DSL vs NAMS Comparison
DSL vs NAMS Comparison
Compare DSL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- NAMS
- Stock Information
- Founded
- DSL 2013
- NAMS 2019
- Country
- DSL United States
- NAMS Netherlands
- Employees
- DSL N/A
- NAMS N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- NAMS Health Care
- Exchange
- DSL Nasdaq
- NAMS Nasdaq
- Market Cap
- DSL 1.4B
- NAMS 1.7B
- IPO Year
- DSL N/A
- NAMS N/A
- Fundamental
- Price
- DSL $12.62
- NAMS $26.75
- Analyst Decision
- DSL
- NAMS Strong Buy
- Analyst Count
- DSL 0
- NAMS 6
- Target Price
- DSL N/A
- NAMS $36.20
- AVG Volume (30 Days)
- DSL 412.7K
- NAMS 1.4M
- Earning Date
- DSL 01-01-0001
- NAMS 02-06-2025
- Dividend Yield
- DSL 10.30%
- NAMS N/A
- EPS Growth
- DSL N/A
- NAMS N/A
- EPS
- DSL N/A
- NAMS N/A
- Revenue
- DSL N/A
- NAMS $33,594,000.00
- Revenue This Year
- DSL N/A
- NAMS $129.49
- Revenue Next Year
- DSL N/A
- NAMS N/A
- P/E Ratio
- DSL N/A
- NAMS N/A
- Revenue Growth
- DSL N/A
- NAMS 78.77
- 52 Week Low
- DSL $10.22
- NAMS $10.29
- 52 Week High
- DSL $12.96
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- DSL 39.54
- NAMS 68.38
- Support Level
- DSL $12.59
- NAMS $24.40
- Resistance Level
- DSL $12.95
- NAMS $27.29
- Average True Range (ATR)
- DSL 0.08
- NAMS 1.57
- MACD
- DSL -0.02
- NAMS 0.63
- Stochastic Oscillator
- DSL 5.08
- NAMS 94.52
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.